Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Status:
Completed
Trial end date:
2017-04-14
Target enrollment:
Participant gender:
Summary
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of
NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment. This study will
enroll approximately 90 male and female pediatric subjects clinically diagnosed with Tourette
Syndrome.